20
Participants
Start Date
April 7, 2021
Primary Completion Date
February 28, 2026
Study Completion Date
July 28, 2027
Risankizumab-Rzaa
Risankizumab at a dose of 150 mg with injections administered at baseline, week 4 and week 16 following FDA-approved dosage and time periods
Punch biopsies of the skin at baseline visit
Two 6 mm punch biopsies of the skin at baseline visit
Punch biopsies of the skin at week 28 visit
One 6 mm punch biopsy of the skin at week 28 visit
The Rockefeller Univesity, New York
VA Northern California Health Care System, Sacramento
University of California Davis Medical Center, Sacramento
Collaborators (1)
AbbVie
INDUSTRY
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Jaehwan Kim
OTHER